Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sovleplenib (HMPL-523) in Adult Immune Thrombocytopenia
NCT06291415Phase 1Withdrawn
- Sponsor
- HUTCHMED
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, randomised, open-label trial of sovleplenib in immune thrombocytopenia (ITP) (5 arms), sponsored by HUTCHMED. Primary endpoints: Safety and tolerability of HMPL-523 and Dose Limiting Toxicities. Planned start Apr 2024; status: withdrawn.
02
Drugs
sovleplenib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06291415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06291415.